Erratum: The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months (Pharmacoepidemiology and Drug Safety (2007) vol. 16 (726-735) 10.1002/pds.1294);The new Swedish Prescribed Drug Register Opportunities for pharmacoepidemiological research and experience from the first six months

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 7, 2007, Pages 726-735

  Wettermark, Björn ^a,b,c   Hammar, Niklas ^c,d   Fored, C Michael ^a,c   Leimanis, Andrejs ^e   Olausson, Petra Otterblad ^e   Bergman, Ulf ^a   Persson, Ingemar ^c,f   Sundström, Anders ^g   Westerholm, Barbro ^g   Rosén, Måns ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Apoteket AB   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e CENTRE FOR EPIDEMIOLOGY   (Sweden)

^f MEDICAL PRODUCTS AGENCY   (Sweden)

^g Swedish Association of Senior Citizens   (Sweden)

Author keywords

Drug utilization; Pharmacoepidemiology; Record linkage; Register; Sweden

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; ANTIVITAMIN K; ANXIOLYTIC AGENT; CONTRACEPTIVE AGENT; CORTICOSTEROID; DERMATOLOGICAL AGENT; DIGESTIVE TRACT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GLUCOCORTICOID; HYPNOTIC AGENT; INSULIN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL ANTIDIABETIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DRUG COST; DRUG EXPOSURE; DRUG USE; DRUG UTILIZATION; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; SWEDEN;

EID: 34547504685     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1604     Document Type: Erratum

References (38)

1. Strom B. (ed.). Pharmacoepidemiology (4th edn). John Wiley & Sons: Chichester, 2005.
2. Bergman U. Pharmacoepidemiological perspectives. Journal of Clinical Epidemiology 1992; 45: 313-317.
3. Bergström K, Westerholm B. Consumption of sedatives, hypnotics and minor tranquillizers in a Swedish town. In Psychiatry. V World Congress of Psychiatry, Mexico, De la Fuente R, Weisman MN (eds). Excerpta Medica: Amsterdam, 1971.
4. Boethius G, Wiman F. Recording of drug prescription in the county of Jämtland, Sweden. I. Methodological aspects. Eur J Clin Pharmacol 1977; 12: 31-35.
5. Isacson D, Stålhammar J. Prescription Drug use among diabetics - a population study. J Chron Dis 1987; 40: 651-660.
6. Bergman U. Pharmacoepidemiology - from description to quality assessment. A Swedish perspective. Norwegian Journal of Epidemiology 2001; 11: 31-36.
7. National Board of Health and Welfare. A finger on the pulse.- Monitoring public health and social conditions in Sweden 1992-2002. Centre for Epidemiology, National Board of Health and Welfare: Stockholm: 2003. (The report can be downloaded from www.sos.se/ epc).
8. Garpenby P, Carlsson P. The role of national quality registers in the Swedish health service. Health Policy 1994; 29: 183-195.
9. World Health Organization (WHO) Oslo. Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, 2005. www.whocc.no
10. Apoteket AB. Svensk Läkemedelsstatistik (Swedish Drug statistics). 2005. Sales of medicines in Sweden. Swedish National Corporation of Pharmacies. www.apoteket.se
11. Bergman U, Sjöqvist F. Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Medica Scandinavia 1984; 105(suppl 683): 15-22.
12. Rochat P, Hallas J, Gaist D, Friis ML. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 2001; 104: 6-11.
13. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf 2001; 10: 549-554.
14. Wettermark B, Hjemdahl P. Har vi råd med en bra kolesterolsänkande behandling? Budgetunderlag för behovsbaserade statinkostnader i Stockholms län [Can we afford good cholesterol lowering therapy? Budgeting of statin costs versus medical needs in the county of Stockholm]. Läkartidningen 2001; 98: 5472-5483.
15. von Euler M, Eliasson E, Ohlen G, Bergman U. Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf 2006; 15: 179-184.
16. Haaijer-Ruskamp FM, Hoven JL, Mol PGM. A conceptual framework for constructing prescribing quality indicators: a proposal. DURQUIM: Drug utilization quality indicator meeting. Mechelen, Belgium WHO Europe. 2004.
17. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-233.
18. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications; a cross-national study. JAMA 1998; 279: 1458-1462.
19. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005; 59: 564-573.
20. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering Drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463-471.
21. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997; 53: 185-189.
22. Källén B. Omeprazole during pregnancy - no hazard demontrated in 955 infants exposed during pregnancy. Europ J Obste Gynecol Repr Biol 2001; 96: 63-68.
23. Källén B, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reproductive Toxicology 2005; 20: 209-214.
24. Norjavaara E, Gerhardsson de Verdier M, Lindmark B. Adult height in women with childhood asthma - a population-based study. Pharmacoepidemiol Drug Saf 2001; 10: 121-125.
25. Ericson A, Källén B, Åberg A. Use of multivitamins and folic acid in early pregnancy and multiple births. Twin Res 2001; 4: 63-66.
26. Morris LS, Schulz RM. Patient compliance-an overview. J Clin Pharm Ther 1992; 17: 283-295.
27. World Health Organization (WHO). Adherence to Long-term therapies: evidence for action. 2003.
28. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA 2002; 287: 337-344.
29. Sundström A, Jansson K, Wiholm BE. The CCNET Control-Pool: a database of 2000 randomly selected community controls in Sweden. Abstract presented at the '8th Annual Meeting - European Society of Pharmacovigilance', Verona September 2000. Conference-book edited by Giampaolo Velo and Roberto Leone (Elsevier).
30. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-1731.
31. International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-595. http://www.pharmacoepi.org/resources/ policies.cfm
32. Swedish Health Data Registers Act (1998: 543).
33. International Society of Pharmacoepidemiology (ISPE). Guidelines for Good Practice in Data Privacy, Medical Record Confidentiality, and Research in the interest of Public Health. http://www.pharmacoepi.org/ resources/privacy.cfm
34. Merz JF (ed.). A survey of international ethics practices in pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2001; 10: 577-708.
35. Wilson P. Legal issues of data anonymisation in research. BMJ 2004; 328: 1300-1301.
36. Klaukka T. The Finnish database on drug utilisation. Norwegian Journal of Epidemiology 2001; 11: 19-22.
37. Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk. (Article in Norwegian) Norsk Epidemiologi 2004; 14(1): 53-55.
38. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-448.